ClinicalTrials.gg
Not yet recruitingNCT06657339Updated Oct 24, 2024

National Registry of Obesity Treatment by Endosleeve

An observational study in Obesity, sponsored by Société Française d'Endoscopie Digestive. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Société Française d'Endoscopie Digestive · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
354
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Obesity and overweight have emerged as public health problems of a pandemic nature, significantly reducing the life expectancy of those affected. Obesity has a considerable medico-economic impact, linked to the treatments it requires and its comorbidities. Currently, the prevention of obesity in our Western societies is not effective enough, as the prevalence and incidence of obesity and overweight continue to rise worldwide. In France, the therapeutic management of this condition is governed by the HAS and is summarized as a surgical approach for type 2 obesity with comorbidity or type 3 obesity, with three authorized methods that have shown sufficient evidence: gastric banding, sleeve gastrectomy (or longitudinal sleeve gastrectomy), and Roux-en-Y gastric bypass.

With the advent of organ-preserving interventional endoscopy, the systematic use of these surgical methods, although effective for total weight loss and excess weight loss, raises questions. Indeed, these new therapeutic endoscopic approaches, which are less invasive, less costly, and respectful of anatomy, currently show convincing cohort results in the short term (12 to 24 months) and require confirmation of their effectiveness and safety in the long term (5 years) so that they can become first-line therapeutic methods in the near future. At the request of the HAS in its self-referral of 2020 and then in 2022, this prospective registry aims to confirm the effectiveness and safety of the endosleeve (or endoscopic sleeve) in the long-term therapeutic management of obesity within the framework of everyday practice in national reference centers for obesity treatment.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Endosleeve
  • Endoscopic gastroplasty
  • Endoscopic suture
03

In context

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 354 is above the median of 115 across 2,159 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Société Française d'Endoscopie Digestive is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any referred patient with obesity and a BMI > 30 kg/m² who meets the inclusion criteria and is considered suitable for therapeutic management of obesity will be invited to participate in the study at the investigating centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years;
  • Patient with a (BMI) ≥ 30 kg/m²;
  • Signed

Exclusion criteria

Exclusion Criteria:

  • to performing an upper endoscopy or using an endoscopic plication system according to the instructions for use (IFU);
  • Presence of an ulcer in the gastric body or fundus;
  • Achalasia, severe esophagitis (Los Angeles grade C or D);
  • ENT or esophageal malformation;
  • Gastrointestinal disease (including stenosis), history of previous gastric surgery (including bariatric surgery, previous endoscopic gastroplasty);
  • Congestive gastropathy, gastric polyposis, gastric or esophageal varices, risk of gastric tumor disease due to personal or family history;
  • Positive Helicobacter pylori status with failed eradication treatments;
  • Uncontrolled or severe eating disorder or psychiatric illness;
  • Substance abuse or chronic alcoholism;
  • Severe renal insufficiency (stage 4 or 5), Cirrhosis Child B or C;
  • Anticoagulant or antiplatelet treatment that cannot be stopped or replaced according to international recommendations (ESGE 2021);
  • Coagulation or hemostasis disorders (PT \< 60%, \< 60,000/mm³);
  • Mental deficiency of the subject making participation in the trial impossible;
  • Patient not affiliated with a social security scheme;
  • Pregnant women, breastfeeding individuals;
  • Inability to understand or sign the .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
354 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Endoscopic sleeve gastroplasty

    Therapeutic endoscopy using a gastric suturing device (OverStitch™/Endomina™) according to the practices of the investigating center

    Procedure: Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)

Interventions

  • ProcedureTherapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)

    The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting. Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach.

06

What researchers measure

Primary outcomes

  1. Measurement of total weight loss (TWL) in % 5 years afther endosleeve

    To determine the proportion of patients who met the PIVI criteria after endosleeve without additional techniques

    Time frame: 5 years

Secondary outcomes

  1. Measurement of total weight loss (TWL) in %

    Determine total weight loss (TWL) afther endosleeve at 12, 24 months,

    Time frame: 12 et 24 months

  2. Measurement excess weight loss after the endosleeve intervention.

    Determine excess weight loss (EWL) after the endosleeve intervention, with positivity established by the PIVI criteria (EWL \> 25% at 12 months), and evaluate the long-term evolution of this EWL

    Time frame: 12, 24 months, and 5 years

  3. Measurement of the percentage of postoperative complications according to the AGREE classification

    The safety of this procedure will be evaluated by recording complications perioperatively (Day 1) and post-procedure (Day 30) according to the AGREE criteria and using the PIVI criteria (positive if the complication rate is \< 5%).

    Time frame: Day 1 and Day 30.

  4. Measurement of remission (or regression) of pre-existing comorbidities

    Determine the impact on pre-existing metabolic comorbidities : 1. Diabetes remission = HbA1C \< 6.5%, 3 months after discontinuation of all treatment / Regression or improvement of diabetes involving a decrease of more than 0.5% in HbA1C according to recognized criteria 2. Hypertension = Systolic blood pressure (SBP) \< 140 mmHg and/or Diastolic blood pressure (DBP) \< 90 mmHg without any treatment / Decrease in the number of therapeutic classes; 3. Obstructive Sleep Apnea Syndrome (OSAS) = Number of apneas less than 5 without equipment / Decrease in OSAS stage = mild (5 to 15 per hour), moderate (15 to 30), or severe (more than 30) with or without equipment; 4. Steatohepatitis = quantification by MRI of the % of fat in the liver with a decrease of more than 30%; 5. Dyslipidemia = normalization or improvement of LDL cholesterol and triglyceride levels without the addition of new drug therapies.

    Time frame: 12 months, 24 months, and 5 years.

  5. Occurrence of metabolic comorbidities

    The occurrence of metabolic comorbidities such as diabetes, hypertension (HTN), obstructive sleep apnea syndrome (OSAS), steatohepatitis, and dyslipidemia will be assessed at 12, 24 months, and at the end of the follow-up period. Each comorbidity will be evaluated according to its specific definitional criteria

    Time frame: 12 months, 24 months, and 5 years

  6. Outpatient procedures

    Number of outpatient procedures performed without the need for readmission within 30 days of follow-up

    Time frame: 30 days

  7. Bariatric procedures performed following the initial intervention

    Number and type of bariatric procedures performed following the initial intervention (Redo EndoSleeve, medication treatment such as GLP-1 agonists or equivalent, instrumental treatment with a balloon or other methods)

    Time frame: Day 1 and Day 30.

  8. Conversion rates in bariatric surgery and their feasibility

    Number of conversions to bariatric surgery (Sleeve and bypass) and their feasibility (whether the procedure was possible)

    Time frame: 3 years and 5 years

  9. Predictive factors for response, weight regain, and plateau at the EndoSleeve

    Determination of predictive factors for response, failure (\<5% total weight loss at 6 months), weight regain (50% of the lost weight regained at or after one year), and plateau with EndoSleeve (≥10% weight loss but no further loss for more than 3 months)

    Time frame: 3 months, 6 months and 1 year

  10. Sequence of bariatric procedures that led to the best weight response

    Description of the sequence of bariatric procedures leading to the best weight loss outcome after 5 years of follow-up

    Time frame: 5 years

  11. Measurement of the improvement in quality of life.

    Impact on quality of life will be measured through quality of life questionnaires (BAROS questionnaire) before the intervention and during each medical visit, to assess psychological health before and after the intervention.

    Time frame: 12 months , 24 months, and at 5 years of follow-up.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Dec 2029, 60 months later.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 60 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 24, 2024
StartEst.
Dec 2024
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06657339
Lead sponsor
Société Française d'Endoscopie Digestive
Responsible party
VANBIERVLIET (Director, Head of Endocopy, Principal Investigator, Medical doctor, Société Française d'Endoscopie Digestive) — Principal investigator
First posted
Oct 24, 2024
Start date
Dec 2024 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 24, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion